HLA

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Agosto 10, 2021
Evelyn, FDA, TCR, Adoptive cell transfer, Acceleration, MAGEA1, Cell, Research institute, Cancer, Development, Neoplasm, Paul Ehrlich Institute, Â, Cancer Prevention and Research Institute of Texas, Patient, Safety, HLA, Twitter, Forward-looking statement, CTA, Family, Research, Conference, Clinical trial, University of Texas Health Science Center at Houston, Investment, European Central Bank, Industry, LinkedIn, EUR, Board, Central bank, Company, NASDAQ, Administration, Cancer prevention, SEC, Terminology, GMP, Board of directors, Partner (business rank), PRAME, CEO, Medical imaging, Cryptocurrency, Fine chemical, Pharmaceutical industry, Vaccine, Animal

An important development during the second quarter of 2021 was a significant increase in patient enrollment for our ACTengine programs, said Harpreet Singh, Ph.D., CEO of Immatics.

Key Points: 
  • An important development during the second quarter of 2021 was a significant increase in patient enrollment for our ACTengine programs, said Harpreet Singh, Ph.D., CEO of Immatics.
  • Our TCER pipeline is further strengthened by our second TCR Bispecifics program, IMA402, for which we recently presented preclinical proof-of-concept data.
  • In March 2021 , Immatics reported initial safety and biological data as well as data showing first clinical anti-tumor activity for 10 patients enrolled in these trials.
  • IMA401 remains on track for submission of a CTA in the fourth quarter of 2021 and patient recruitment will be initiated in the first half 2022.

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Agosto 5, 2021
Acute lymphoblastic leukemia, The Retreat, Cancer, Non-small-cell lung carcinoma, Safety, Clinical trial, Tenant, Annual report, Private Securities Litigation Reform Act, Review, Thalassemia, ESMO, Oncology, Lung cancer, European Society for Medical Oncology, Research, Therapy, Risk, European Society of Gene and Cell Therapy, Transfusion, IND, Limited liability company, Partnership, TCR, Aall, Congress, National Hockey League, Oslo-Fergene, GLOBE, Company, Conference, U.S. Securities and Exchange Commission, Investment, Cholangiocarcinoma, Lymphatic system, Adoption, HLA, Program, Patient, COVID-19, Ovarian cancer, Certification, Adult, Nasdaq, D, Cell, Quality control, Pharmaceutical industry, Animal, Cryptocurrency

Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.

Key Points: 
  • Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.
  • R&D Expenses: Research and development expenses were $18.6 million for the second quarter of 2021 compared to $12.9 million for the second quarter of 2020.
  • G&A Expenses: General and administrative expenses were $5.7 million for the second quarter of 2021 compared to $3.8 million for the second quarter of 2020.
  • Net Loss: Net loss was $24.3 million for the second quarter of 2021 compared to $16.2 million for the second quarter of 2020.

T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

Retrieved on: 
Mercoledì, Agosto 4, 2021
Cancer immunotherapy

SAN FRANCISCO and BERLIN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc. a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for patients with solid tumors, today announced the appointment of cell therapy and immuno-oncology thought leader, Peggy Sotiropoulou, Ph.D., as its Chief Scientific Officer.

Key Points: 
  • SAN FRANCISCO and BERLIN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc. a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for patients with solid tumors, today announced the appointment of cell therapy and immuno-oncology thought leader, Peggy Sotiropoulou, Ph.D., as its Chief Scientific Officer.
  • We are delighted to welcome Peggy to T-knifes senior leadership team, stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • Peggy brings over 20 years of successful experience in oncology research and development, with notable contributions to the field as both a scientist and drug developer.
  • Peggys thought leadership in next-generation T cell technologies will greatly benefit T-knife as we continue to expand our pipeline and technology platforms.

Caris Life Sciences Launches HLA Genotype Reporting, the Newest Addition to its Suite of Comprehensive Molecular Science Offerings

Retrieved on: 
Mercoledì, Marzo 24, 2021
Medical specialties, Clinical medicine, Health, HLA, Precision medicine, Sjögren syndrome

IRVING, Texas, March 24, 2021 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced the launch of Human Leukocyte Antigen (HLA) Genotype reporting, the newest addition to the Company's suite of comprehensive molecular science offerings.

Key Points: 
  • IRVING, Texas, March 24, 2021 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced the launch of Human Leukocyte Antigen (HLA) Genotype reporting, the newest addition to the Company's suite of comprehensive molecular science offerings.
  • Caris HLA Genotype reporting builds upon the most expansive molecular intelligence available and strengthens physicians' ability to provide more individualized treatment decisions for their patients.
  • HLA Genotype results may also provide additional insight for patient enrollment into clinical trials and patients' response to immunotherapy.
  • Caris Life Sciencesis a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation.

CareDx Leads in Innovation with AlloSeq Portfolio at ASHI 2020

Retrieved on: 
Lunedì, Ottobre 19, 2020
HLA, Ashi

ASHI will be hosted virtually from October 19th 21st 2020.

Key Points: 
  • ASHI will be hosted virtually from October 19th 21st 2020.
  • At ASHI 2020, CareDx will host a virtual symposium, a virtual happy hour, and several meet-the-expert sessions.
  • I am glad that CareDx is leveraging this Virtual ASHI platformand engaging this community while offering collaborative and innovative talks during this conference.
  • Each year ASHI allows us to update the HLA laboratory community on the work that CareDx is doing in the field of immunogenetics and transplant immunology, said Peter Maag, CEO of CareDx.

Omixon at the EFI Annual Meeting 2019

Retrieved on: 
Martedì, Aprile 30, 2019
HLA, Academic journals, Publications, Periodicals

BUDAPEST, Hungary and CAMBRIDGE, Mass., April 30, 2019 /PRNewswire-PRWeb/ -- Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announces today that Holotype HLA and other Omixon products will be featured in 12 poster presentations at the annual meeting of the European Federation for Immunogenetics (EFI) in Lisbon, Portugal.

Key Points: 
  • BUDAPEST, Hungary and CAMBRIDGE, Mass., April 30, 2019 /PRNewswire-PRWeb/ -- Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announces today that Holotype HLA and other Omixon products will be featured in 12 poster presentations at the annual meeting of the European Federation for Immunogenetics (EFI) in Lisbon, Portugal.
  • "Omixon is extremely proud to see how Holotype HLA has shaped the scientific and technical output of our customers in the EFI Community", says Omixon's CEO, Dr. Peter Meintjes.
  • (2019) - Automating Holotype HLA on Eppendorf's epMotion Liquid Handler and Validating it for Routine HLA Typing
    P219 | Mette Christiansen et al.
  • (2019) - Evaluation of Omixon Holotype HLA on the iSeq 100 Instrument
    P223 | Elena Shagimardanova et al.